FMP
Enter
API Tools
Kazia Therapeutics Limited
KZIA
NASDAQ
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
0.34 USD
-0.0031 (-0.912%)
Valuation Date:
Apr 18, 2024 11:02 AM
Share Price on Valuation Date
$0.34
Stock Beta
2.113
Shares Outstanding
19981871
